• NN received initial purchase orders to supply precision components for a leading robotic-assisted surgery platform, following qualification.
• The orders follow a full-facility quality audit passed at its Kentwood, Michigan plant, enabling medical certification for production.
• The company estimated its medical new-business pipeline rose by about USD 25 million to roughly USD 75 million.
• Total corporate new-business pipeline was pegged at more than USD 750 million.
• NN expects to review 2026 sales, adjusted EBITDA, and new-wins guidance at its August business update.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NN Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607060700PRIMZONEFULLFEED9757119) on July 06, 2026, and is solely responsible for the information contained therein.